Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation

Although ruxolitinib contributes to immunomodulation and can lead to severe infections, it seems a feasible treatment strategy for patients with polycythemia vera and myelofibrosis after liver transplantation.

Detalles Bibliográficos
Autores principales: Dold, Leona, Lutz, Philipp, Heine, Annkristin, Weismüller, Tobias J., Strassburg, Christian P., Spengler, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418679/
https://www.ncbi.nlm.nih.gov/pubmed/34504700
http://dx.doi.org/10.1002/ccr3.4782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418679/
https://www.ncbi.nlm.nih.gov/pubmed/34504700
http://dx.doi.org/10.1002/ccr3.4782

Ejemplares similares